Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The audit was completed with zero critical and zero major observations
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
GV20 received an upfront payment and is eligible for additional milestone payments
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Renalyx will continue operating as an independent unit within the group
Subscribe To Our Newsletter & Stay Updated
